메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
This study was performed to confirm the safety of the silk amino acids (SAA). Male and female Sprague-Dawley rats were orally administered with SAA at dose levels of 500, 1,000 or 2,000 ㎎/㎏ for 4 weeks. There was no significant difference in the body weight gain between vehicle control and SAA-treated rats. Also, significant changes in daily feed and water intakes were not observed. In hematological analysis, SAA decreased the rates of monocytes and eosinophils, while increasing that of lymphocytes, suggestive of reduced inflammatory response and immune potentiation. In particular, SAA significantly increased the numbers of red blood cells, showing microcytic erythropoiesis, and platelets, implying an enhanced hematopoiesis. In blood biochemistry, alanine transaminase, aspartate transaminase and lactate dehydrogenase were significantly reduced by SAA treatment, in contrast to the increases in glucose and albumin. Blood urea nitrogen and creatine phosphokinase also significantly decreased following SAA treatment. In spite of the decreases in the markers of liver, kidneys, skeletal and heart muscles, no remarkable lesions were observed in these organs. Such effects of SAA on the blood markers might be due to the stabilization or protective activities on the active organs, which may lead to enhanced resistance to hyperactivity, hypermotility or excitatory stress. Since no observed adverse-effect level of SAA was found to be higher than the upper-limit dose (2,000 ㎎/㎏), a 20-fold higher level of a clinicallyrecommended dose (100 ㎎/㎏), it is suggested that SAA possess a long-term safety, and that it could be a candidate for the improvement of hematopoiesis and stamina.

목차

재료 및 방법
결과 및 고찰
참고문헌

참고문헌 (16)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0101-2009-510-015707060